Eli Lilly Reports Strong Q3 2025 Financial Results, Advances Pipeline, and Raises Full-Year Guidance
Eli Lilly
Global Pharmaceutical R&D and Production Company
On October 30, 2025, Eli Lilly and Company announced its financial results for the third quarter of 2025.
Key Points of Q3 2025 Earnings Report
➤ Revenue in the third quarter of 2025 increased by 54% year-over-year to reach $17.6 billion, primarily driven by the sales growth of tirzepatide.
➤ In the third quarter of 2025, based on reported financial data, earnings per share (EPS) increased from $5.14 to $6.21; on a non-GAAP adjusted basis, earnings per share grew from $5.84 to $7.02.
➤ Full-year 2025 revenue guidance raised to $63 billion–$63.5 billion range; Earnings Per Share (EPS) guidance increased to $21.80–$22.50 range, and Non-GAAP adjusted EPS guidance raised to $23.00–$23.70 range.
➤ Pipeline Progress: Orforglipron Achieves Positive Results in Four Phase 3 Clinical Trials for Type 2 Diabetes and Obesity, with Plans to Submit Obesity Indication Applications to Global Regulatory Authorities Within the Year.
➤ Drug Approval Progress: U.S. FDA Approves Inluriyo (imlunestrant) for Treatment of Certain Adults with Advanced or Metastatic Breast Cancer.
➤ Capacity Expansion: Eli Lilly and Company announces the construction of two new manufacturing facilities in Virginia and Texas, as well as the expansion of its existing production site in Puerto Rico.
*Disclaimer:
1. The relevant indications for some of the drugs described in this article have not yet been approved in China.
2. Eli Lilly does not recommend the use of any unapproved drugs/indications.
/ Mr. David A. Ricks/
Chairman and Chief Executive Officer of Eli Lilly and Company
“
Driven by the continued strong market demand for incretin-based drugs, Eli Lilly sustained its growth momentum with a 54% year-over-year increase in revenue. Orforglipron achieved positive progress in four Phase 3 clinical trials, laying the groundwork for global submissions of an obesity indication drug application within the year. Meanwhile, Inluriyo (imlunestrant) received approval from the U.S. FDA, marking another significant milestone in our R&D pipeline. We are continuously expanding our production capacity, recently announcing new manufacturing facilities in Virginia and Texas, as well as the expansion of our production site in Puerto Rico.
Lilly
About Eli Lilly and Company
Eli Lilly and Company is a pharmaceutical company dedicated to improving human health through scientific innovation and benefiting patients worldwide. As a leader in the healthcare industry, Eli Lilly and Company has nearly 150 years of history. Today, our medicines have helped tens of millions of people globally. Harnessing the power of biotechnology, chemistry, and genomic medicine, our scientists are actively advancing new medical breakthroughs to address severe global health challenges. We are redefining therapies for diabetes and obesity, reducing the long-term impact of obesity on the body; supporting prevention and treatment efforts for Alzheimer's disease; providing solutions for a range of immune-mediated diseases that threaten human health; and transforming difficult-to-treat cancers into manageable conditions. Every step Eli Lilly and Company takes toward a healthier world is rooted in our belief of "commitment to making life better for millions of patients." This includes innovative clinical trials aimed at addressing multiple global challenges, while ensuring the accessibility and affordability of medicines. For more information about Eli Lilly and Company, please visit: www.lilly.com.cn.
PP-MG-CN-4229